Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 534320, 13 pages
http://dx.doi.org/10.1155/2015/534320
Review Article

Differential Role of Leptin and Adiponectin in Cardiovascular System

1Department of Anatomy, Cell biology and Physiology, American University of Beirut, DTS-255, P.O. Box 11-0236, Beirut 1107-2020, Lebanon
2Department of Pharmacology and Toxicology, American University of Beirut, DTS-255, P.O. Box 11-0236, Beirut 1107-2020, Lebanon

Received 7 December 2014; Accepted 23 April 2015

Academic Editor: Alexander Schreiber

Copyright © 2015 C. M. Ghantous et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Weiss, S. Dufour, A. Groszmann et al., “Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2014–2018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Lee, D. R. Reed, and R. A. Price, “Leptin resistance is associated with extreme obesity and aggregates in families,” International Journal of Obesity, vol. 25, no. 10, pp. 1471–1473, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Friedman and J. L. Halaas, “Leptin and the regulation of body weight in mammals,” Nature, vol. 395, no. 6704, pp. 763–770, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Huang and C. Li, “Leptin: a multifunctional hormone,” Cell Research, vol. 10, no. 2, pp. 81–92, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Zeidan and M. Karmazyn, “Leptin and vascular smooth muscle,” Current Vascular Pharmacology, vol. 4, no. 4, pp. 383–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Campfield, F. J. Smith, and P. Burn, “The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks,” Hormone and Metabolic Research, vol. 28, no. 12, pp. 619–632, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Matsui, M. Motooka, H. Koike et al., “Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression,” Life Sciences, vol. 80, no. 7, pp. 672–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Zeidan, D. M. Purdham, V. Rajapurohitam, S. Javadov, S. Chakrabarti, and M. Karmazyn, “Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 1075–1084, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S.-C. Chen, J. P. Kochan, L. A. Campfield, P. Burn, and R. J. Smeyne, “Splice variants of the OB receptor gene are differentially expressed in brain and peripheral tissues of mice,” Journal of Receptor and Signal Transduction Research, vol. 19, no. 1–4, pp. 245–266, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Marroquí, A. Gonzalez, P. Neco et al., “Role of leptin in the pancreatic β-cell: effects and signaling pathways,” Journal of Molecular Endocrinology, vol. 49, no. 1, pp. R9–R17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Hall, G. Smith, J. E. Hall, and D. E. Stec, “Cardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 303, no. 12, pp. R1241–R1250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. P. Briscoe, S. Hanif, J. R. S. Arch, and M. Tadayyon, “Leptin receptor long-form signalling in a human liver cell line,” Cytokine, vol. 14, no. 4, pp. 225–229, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Wolf, S. Chen, D. C. Han, and F. N. Ziyadeh, “Leptin and renal disease,” American Journal of Kidney Diseases, vol. 39, no. 1, pp. 1–11, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Rajapurohitam, X. T. Gan, L. A. Kirshenbaum, and M. Karmazyn, “The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes,” Circulation Research, vol. 93, no. 4, pp. 277–279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Mütze, J. Roth, R. Gerstberger, K. Matsumura, and T. Hübschle, “Immunohistochemical evidence of functional leptin receptor expression in neuronal and endothelial cells of the rat brain,” Neuroscience Letters, vol. 394, no. 2, pp. 105–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Markowska, A. S. Belloni, M. Ructnski et al., “Leptin and leptin receptor expression in the myometrium and uterine myomas: is leptin involved in tumor development?” International Journal of Oncology, vol. 27, no. 6, pp. 1505–1509, 2005. View at Google Scholar · View at Scopus
  17. C. Bjørbæk, S. Uotani, B. da Silva, and J. S. Flier, “Divergent signaling capacities of the long and short isoforms of the leptin receptor,” The Journal of Biological Chemistry, vol. 272, no. 51, pp. 32686–32695, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Knudson, Ü. D. Dincer, C. Zhang et al., “Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction,” The American Journal of Physiology: Heart and Circulatory Physiology, vol. 289, no. 1, pp. H48–H56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Margetic, C. Gazzola, G. G. Pegg, and R. A. Hill, “Leptin: a review of its peripheral actions and interactions,” International Journal of Obesity, vol. 26, no. 11, pp. 1407–1433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Rahmouni and W. G. Haynes, “Leptin and the cardiovascular system,” Recent Progress in Hormone Research, vol. 59, pp. 225–244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Fernández-Riejos, S. Najib, J. Santos-Alvarez et al., “Role of leptin in the activation of immune cells,” Mediators of Inflammation, vol. 2010, Article ID 568343, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Sinha, I. Opentanova, J. P. Ohannesian et al., “Evidence of free and bound leptin in human circulation: studies in lean and obese subjects and during short-term fasting,” Journal of Clinical Investigation, vol. 98, no. 6, pp. 1277–1282, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Fried, M. R. Ricci, C. D. Russell, and B. Laferrere, “Regulation of leptin production in humans,” Journal of Nutrition, vol. 130, pp. 3127S–3131S, 2000. View at Google Scholar
  24. R. A. Coleman and T. S. Herrmann, “Nutritional regulation of leptin in humans,” Diabetologia, vol. 42, no. 6, pp. 639–646, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. T. G. Ramsay and M. P. Richards, “Leptin and leptin receptor expression in skeletal muscle and adipose tissue in response to in vivo porcine somatotropin treatment,” Journal of Animal Science, vol. 83, no. 11, pp. 2501–2508, 2005. View at Google Scholar · View at Scopus
  26. G.-H. Lee, R. Proenca, J. M. Montez et al., “Abnormal splicing of the leptin receptor in diabetic mice,” Nature, vol. 379, no. 6566, pp. 632–635, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Ge, L. Huang, T. Pourbahrami, and C. Li, “Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 45898–45903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. R. S. Ahima and S. Y. Osei, “Leptin signaling,” Physiology and Behavior, vol. 81, no. 2, pp. 223–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Vaisse, J. L. Halaas, C. M. Horvath, J. E. Dernell Jr., M. Stoffel, and J. M. Friedman, “Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice,” Nature Genetics, vol. 14, no. 1, pp. 95–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. D. W. White, K. K. Kuropatwinski, R. Devos, H. Baumann, and L. A. Tartaglia, “Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization,” The Journal of Biological Chemistry, vol. 272, no. 7, pp. 4065–4071, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Nakashima, M. Narazaki, and T. Taga, “Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130,” FEBS Letters, vol. 403, no. 1, pp. 79–82, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Kloek, A. K. Haq, S. L. Dunn, H. J. Lavery, A. S. Banks, and M. G. Myers Jr., “Regulation of Jak kinases by intracellular leptin receptor sequences,” The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41547–41555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. A. S. Banks, S. M. Davis, S. H. Bates, and M. G. Myers Jr., “Activation of downstream signals by the long form of the leptin receptor,” Journal of Biological Chemistry, vol. 275, no. 19, pp. 14563–14572, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Eyckerman, D. Broekaert, A. Verhee, J. Vandekerckhove, and J. Tavernier, “Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor,” FEBS Letters, vol. 486, no. 1, pp. 33–37, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Hekerman, J. Zeidler, S. Bamberg-Lemper et al., “Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines,” FEBS Journal, vol. 272, no. 1, pp. 109–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. S. H. Bates and M. G. Myers, “The role of leptinSTAT3 signaling in neuroendocrine function: an integrative perspective,” Journal of Molecular Medicine, vol. 82, no. 1, pp. 12–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Münzberg, M. Björnholm, S. H. Bates, and M. G. Myers Jr., “Leptin receptor action and mechanisms of leptin resistance,” Cellular and Molecular Life Sciences, vol. 62, no. 6, pp. 642–652, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Bjørbæk, R. M. Buchholz, S. M. Davis et al., “Divergent roles of SHP-2 in ERK activation by leptin receptors,” The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4747–4755, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. S. L. Dunn, M. Björnholm, S. H. Bates, Z. Chen, M. Seifert, and M. G. Myers Jr., “Feedback inhibition of leptin receptor/Jak2 signaling via Tyr 1138 of the leptin receptor and suppressor of cytokine signaling 3,” Molecular Endocrinology, vol. 19, no. 4, pp. 925–938, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. H. Bates and M. G. Myers Jr., “The role of leptin receptor signaling in feeding and neuroendocrine function,” Trends in Endocrinology and Metabolism, vol. 14, no. 10, pp. 447–452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. K. D. Niswender, B. Gallis, J. E. Blevins, M. A. Corson, M. W. Schwartz, and D. G. Baskin, “Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin,” Journal of Histochemistry and Cytochemistry, vol. 51, no. 3, pp. 275–283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. C. C. T. Smith, M. M. Mocanu, S. M. Davidson, A. M. Wynne, J. C. Simpkin, and D. M. Yellon, “Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects,” British Journal of Pharmacology, vol. 149, no. 1, pp. 5–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Tajmir, R. B. Ceddia, R.-K. Li, I. R. Coe, and G. Sweeney, “Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways,” Endocrinology, vol. 145, no. 4, pp. 1550–1555, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. R. S. Ahima and J. S. Flier, “Leptin,” Annual Review of Physiology, vol. 62, pp. 413–437, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. M. R. Stofega, J. Herrington, N. Billestrup, and C. Carter-Su, “Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B,” Molecular Endocrinology, vol. 14, no. 9, pp. 1338–1350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. O. Gualillo, S. Eiras, D. W. White, C. Diéguez, and F. F. Casanueva, “Leptin promotes the tyrosine phosphorylation of SHC proteins and SHC association with GRB2,” Molecular and Cellular Endocrinology, vol. 190, no. 1-2, pp. 83–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. V. Y. Raju, M. Zheng, K. H. Schuleri et al., “Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptin-resistant obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 11, pp. 4222–4227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Wang, S. Huang, V. P. Sah et al., “Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family,” The Journal of Biological Chemistry, vol. 273, no. 4, pp. 2161–2168, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. H.-J. Shin, J. Oh, S. M. Kang et al., “Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 329, no. 1, pp. 18–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Ohashi, K. Nagata, M. Maekawa, T. Ishizaki, S. Narumiya, and K. Mizuno, “Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop,” The Journal of Biological Chemistry, vol. 275, no. 5, pp. 3577–3582, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Zeidan, B. Paylor, K. J. Steinhoff et al., “Actin cytoskeleton dynamics promotes leptin-induced vascular smooth muscle hypertrophy via RhoA/ROCK- and phosphatidylinositol 3-kinase/protein kinase B-dependent pathways,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 3, pp. 1110–1116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. T. J. Nelson, R. Balza Jr., Q. Xiao, and R. P. Misra, “SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 3, pp. 479–489, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Zeidan, S. Javadov, and M. Karmazyn, “Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes,” Cardiovascular Research, vol. 72, no. 1, pp. 101–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan, “Leptin as a cardiac hypertrophic factor: a potential target for therapeutics,” Trends in Cardiovascular Medicine, vol. 17, no. 6, pp. 206–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Lieb, L. M. Sullivan, T. B. Harris et al., “Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals,” Diabetes Care, vol. 32, no. 4, pp. 612–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. B. H. Lorell and B. A. Carabello, “Left ventricular hypertrophy: pathogenesis, detection, and prognosis,” Circulation, vol. 102, no. 4, pp. 470–479, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Levy, J. M. Murabito, K. M. Anderson, J. C. Christiansen, and W. P. Castelli, “Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study,” Clinical and Experimental Hypertension A: Theory and Practice, vol. 14, no. 1-2, pp. 85–97, 1992. View at Google Scholar · View at Scopus
  58. J. C. Tardiff, “Cardiac hypertrophy: stressing out the heart,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1467–1470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. W. Haider, M. G. Larson, E. J. Benjamin, and D. Levy, “Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death,” Journal of the American College of Cardiology, vol. 32, no. 5, pp. 1454–1459, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Yang and L. A. Barouch, “Leptin signaling and obesity: cardiovascular consequences,” Circulation Research, vol. 101, no. 6, pp. 545–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. L. A. Barouch, D. E. Berkowitz, R. W. Harrison, C. P. O'Donnell, and J. M. Hare, “Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice,” Circulation, vol. 108, no. 6, pp. 754–759, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. W. T. Gibson, I. S. Farooqi, M. Moreau et al., “Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4821–4826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Paz-Filho, C. Mastronardi, T. Delibasi, M.-L. Wong, and J. Licinio, “Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 54, no. 8, pp. 690–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. P. E. Bravo, S. Morse, D. M. Borne, E. A. Aguilar, and E. Reisin, “Leptin and hypertension in obesity,” Vascular Health and Risk Management, vol. 2, no. 2, pp. 163–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Pladevall, K. Williams, H. Guyer et al., “The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study,” Journal of Hypertension, vol. 21, no. 8, pp. 1467–1473, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. M. A. Allison, D. A. Bluemke, R. McClelland et al., “Relation of leptin to left ventricular hypertrophy (from the multi-ethnic study of atherosclerosis),” The American Journal of Cardiology, vol. 112, no. 5, pp. 726–730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Mapfei, J. Halaas, E. Ravussin et al., “Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects,” Nature Medicine, vol. 1, no. 11, pp. 1155–1161, 1995. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Shioi, P. M. Kang, P. S. Douglas et al., “The conserved phosphoinositide 3-kinase pathway determines heart size in mice,” The EMBO Journal, vol. 19, no. 11, pp. 2537–2548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. Y.-K. Kim, S.-J. Kim, A. Yatani et al., “Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt,” The Journal of Biological Chemistry, vol. 278, no. 48, pp. 47622–47628, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. J. R. McMullen, M. C. Sherwood, O. Tarnavski et al., “Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload,” Circulation, vol. 109, no. 24, pp. 3050–3055, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Perego, P. Pizzocri, D. Corradi et al., “Circulating leptin correlates with left ventricular mass in morbid (Grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 4087–4093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Paolisso, M. R. Tagliamonte, M. Galderisi et al., “Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men,” Hypertension, vol. 34, no. 5, pp. 1047–1052, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. R. M. Casto, J. M. VanNess, and J. M. Overton, “Effects of central leptin administration on blood pressure in normotensive rats,” Neuroscience Letters, vol. 246, no. 1, pp. 29–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. E. W. Shek, M. W. Brands, and J. E. Hall, “Chronic leptin infusion increases arterial pressure,” Hypertension, vol. 31, no. 1, pp. 409–414, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Shimizu, N. Sugihara, Y. Kita et al., “Long term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy,” British Heart Journal, vol. 67, no. 2, pp. 155–160, 1992. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Paolisso, M. Galderisi, M. R. Tagliamonte et al., “Myocardial wall thickness and left ventricular geometry in hypertensives: relationship with insulin,” American Journal of Hypertension, vol. 10, no. 11, pp. 1250–1256, 1997. View at Publisher · View at Google Scholar · View at Scopus
  77. K. K. Hintz, N. S. Aberle II, and J. Ren, “Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes,” International Journal of Obesity, vol. 27, no. 10, pp. 1196–1203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. G. M. Reaven, H. Lithell, and L. Landsberg, “Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system,” The New England Journal of Medicine, vol. 334, no. 6, pp. 374–381, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. M. L. G. Correia, D. A. Morgan, W. I. Sivitz, A. L. Mark, and W. G. Haynes, “Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure,” Hypertension, vol. 37, no. 3, pp. 936–942, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Carlyle, O. B. Jones, J. J. Kuo, and J. E. Hall, “Chronic cardiovascular and renal actions of leptin: role of adrenergic activity,” Hypertension, vol. 39, no. 2, pp. 496–501, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Bouloumié, T. Marumo, M. Lafontan, and R. Busse, “Leptin induces oxidative stress in human endothelial cells,” The FASEB Journal, vol. 13, no. 10, pp. 1231–1238, 1999. View at Google Scholar · View at Scopus
  82. S.-I. Yamagishi, D. Edelstein, X.-L. Du, Y. Kaneda, M. Guzmán, and M. Brownlee, “Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A,” Journal of Biological Chemistry, vol. 276, no. 27, pp. 25096–25100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Loffreda, S. Q. Yang, H. Z. Lin et al., “Leptin regulates proinflammatory immune responses,” The FASEB Journal, vol. 12, no. 1, pp. 57–65, 1998. View at Google Scholar · View at Scopus
  84. P. Quehenberger, M. Exner, R. Sunder-Plassmann et al., “Leptin induces endothelin-1 in endothelial cells in vitro,” Circulation Research, vol. 90, no. 6, pp. 711–718, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Grossman, “Does increased oxidative stress cause hypertension?” Diabetes Care, vol. 31, supplement 2, pp. S185–S189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Maingrette and G. Renier, “Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C,” Diabetes, vol. 52, no. 8, pp. 2121–2128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. T. M. Paravicini and R. M. Touyz, “Redox signaling in hypertension,” Cardiovascular Research, vol. 71, no. 2, pp. 247–258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Suganami, M. Mukoyama, K. Mori et al., “Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy,” The FASEB Journal, vol. 19, no. 1, pp. 127–129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Morales-Ruiz, D. Fulton, G. Sowa et al., “Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt,” Circulation Research, vol. 86, no. 8, pp. 892–896, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Oda, T. Taniguchi, and M. Yokoyama, “Leptin stimulates rat aortic smooth muscle cell proliferation and migration,” Kobe Journal of Medical Sciences, vol. 47, no. 3, pp. 141–150, 2001. View at Google Scholar · View at Scopus
  91. S. Goetze, A. Bungenstock, C. Czupalla et al., “Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands,” Hypertension, vol. 40, no. 5, pp. 748–754, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. I. Szanto and C. R. Kahn, “Selective interaction between leptin and insulin signaling pathways in a hepatic cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 5, pp. 2355–2360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Vecchione, A. Maffei, S. Colella et al., “Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway,” Diabetes, vol. 51, no. 1, pp. 168–173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. H.-Y. Park, H. M. Kwon, H. J. Lim et al., “Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro,” Experimental and Molecular Medicine, vol. 33, no. 2, pp. 95–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Kume, K. Satomura, S. Nishisho et al., “Potential role of leptin in endochondral ossification,” Journal of Histochemistry and Cytochemistry, vol. 50, no. 2, pp. 159–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. W. G. Stetler-Stevenson, “Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention,” The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1237–1241, 1999. View at Publisher · View at Google Scholar · View at Scopus
  97. N. Maulik and D. K. Das, “Redox signaling in vascular angiogenesis,” Free Radical Biology and Medicine, vol. 33, no. 8, pp. 1047–1060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. E. Mata-Greenwood, A. Grobe, S. Kumar, Y. Noskina, and S. M. Black, “Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: a requirement for NAD(P)H oxidase,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 289, no. 2, pp. L288–L289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. M. R. Sierra-Honigmann, A. K. Nath, C. Murakami et al., “Biological action of leptin as an angiogenic factor,” Science, vol. 281, no. 5383, pp. 1683–1686, 1998. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Schäfer, M. Halle, C. Goeschen et al., “Leptin promotes vascular remodeling and neointimal growth in mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 1, pp. 112–117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Stephenson, J. Tunstead, A. Tsai, R. Gordon, S. Henderson, and H. M. Dansky, “Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 11, pp. 2027–2033, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Huang, X. Xiong, H. Wang, S. You, and H. Zeng, “Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-κB,” Acta Biochimica et Biophysica Sinica, vol. 42, no. 5, pp. 325–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. K. Kaibuchi, S. Kuroda, and M. Amano, “Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells,” Annual Review of Biochemistry, vol. 68, pp. 459–486, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Nakata, T. Yada, N. Soejima, and I. Maruyama, “Leptin promotes aggregation of human platelets via the long form of its receptor,” Diabetes, vol. 48, no. 2, pp. 426–429, 1999. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Santos-Alvarez, R. Goberna, and V. Sánchez-Margalet, “Human leptin stimulates proliferation and activation of human circulating monocytes,” Cellular Immunology, vol. 194, no. 1, pp. 6–11, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Faggioni, K. R. Feingold, and C. Grunfeld, “Leptin regulation of the immune response and the immunodeficiency of malnutrition,” The FASEB Journal, vol. 15, no. 14, pp. 2565–2571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. G. M. Lord, G. Matarese, J. K. Howard, R. J. Baker, S. R. Bloom, and R. I. Lechler, “Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression,” Nature, vol. 394, no. 6696, pp. 897–901, 1998. View at Publisher · View at Google Scholar · View at Scopus
  108. R. M. Touyz and E. L. Schiffrin, “Reactive oxygen species in vascular biology: implications in hypertension,” Histochemistry and Cell Biology, vol. 122, no. 4, pp. 339–352, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Harrison, K. K. Griendling, U. Landmesser, B. Hornig, and H. Drexler, “Role of oxidative stress in atherosclerosis,” American Journal of Cardiology, vol. 91, no. 3, pp. 7A–11A, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Y. Jun, Z. Ma, R. Pyla, and L. Segar, “Leptin treatment inhibits the progression of atherosclerosis by attenuating hypercholesterolemia in type 1 diabetic Ins2+/Akita:apoE−/− mice,” Atherosclerosis, vol. 225, no. 2, pp. 341–347, 2012. View at Publisher · View at Google Scholar
  112. Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999,” Biochemical and Biophysical Research Communications, vol. 425, no. 3, pp. 560–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Bambace, M. Telesca, E. Zoico et al., “Adiponectin gene expression and adipocyte diameter: a comparison between epicardial and subcutaneous adipose tissue in men,” Cardiovascular Pathology, vol. 20, no. 5, pp. e153–e156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. B. J. Goldstein, R. G. Scalia, and X. L. Ma, “Protective vascular and myocardial effects of adiponectin,” Nature Clinical Practice Cardiovascular Medicine, vol. 6, no. 1, pp. 27–35, 2008. View at Publisher · View at Google Scholar
  115. A. H. Berg, T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer, “The adipocyte-secreted protein Acrp30 enhances hepatic insulin action,” Nature Medicine, vol. 7, no. 8, pp. 947–953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. N. Ouchi, S. Kihara, Y. Arita et al., “Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway,” Circulation, vol. 102, no. 11, pp. 1296–1301, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. W. Zhu, K. K. Y. Cheng, P. M. Vanhoutte, K. S. L. Lam, and A. Xu, “Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention,” Clinical Science, vol. 114, no. 5-6, pp. 361–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Suzuki, E. M. Wilson-Kubalek, D. Wert, T.-S. Tsao, and D. H. Lee, “The oligomeric structure of high molecular weight adiponectin,” The FEBS Letters, vol. 581, no. 5, pp. 809–814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. X. Hui, K. S. Lam, P. M. Vanhoutte, and A. Xu, “Adiponectin and cardiovascular health: an update,” British Journal of Pharmacology, vol. 165, no. 3, pp. 574–590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Saito, T. Tobe, S. Minoshima et al., “Organization of the gene for gelatin-binding protein (GBP28),” Gene, vol. 229, no. 1-2, pp. 67–73, 1999. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Stumvoll, O. Tschritter, A. Fritsche et al., “Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes,” Diabetes, vol. 51, no. 1, pp. 37–41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. H. Ebinuma, T. Miida, T. Yamauchi et al., “Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid,” Clinical Chemistry, vol. 53, no. 8, pp. 1541–1544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. T.-S. Tsao, E. Tomas, H. E. Murrey et al., “Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways,” The Journal of Biological Chemistry, vol. 278, no. 50, pp. 50810–50817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. U. B. Pajvani, X. Du, T. P. Combs et al., “Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9073–9085, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. T. Yamauchi, J. Kamon, Y. Ito et al., “Cloning of adiponectin receptors that mediate antidiabetic metabolic effects,” Nature, vol. 423, no. 6941, pp. 762–769, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. E. Tomas, T.-S. Tsao, A. K. Saha et al., “Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16309–16313, 2002. View at Publisher · View at Google Scholar · View at Scopus
  128. T. Yamauchi, J. Kamon, Y. Minokoshi et al., “Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase,” Nature Medicine, vol. 8, no. 11, pp. 1288–1295, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Yamauchi, Y. Nio, T. Maki et al., “Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions,” Nature Medicine, vol. 13, no. 3, pp. 332–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Bjursell, A. Ahnmark, M. Bohlooly-Y et al., “Opposing effects of adiponectin receptors 1 and 2 on energy metabolism,” Diabetes, vol. 56, no. 3, pp. 583–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Liu, M. D. Michael, S. Kash et al., “Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes,” Endocrinology, vol. 148, no. 2, pp. 683–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Hug, J. Wang, N. S. Ahmad, J. S. Bogan, T.-S. Tsao, and H. F. Lodish, “T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 28, pp. 10308–10313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Takeuchi, Y. Adachi, Y. Ohtsuki, and M. Furihata, “Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease,” Medical Molecular Morphology, vol. 40, no. 3, pp. 115–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. M. S. Denzel, M.-C. Scimia, P. M. Zumstein, K. Walsh, P. Ruiz-Lozano, and B. Ranscht, “T-cadherin is critical for adiponectin-mediated cardioprotection in mice,” The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4342–4352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Shibata, Y. Izumiya, K. Sato et al., “Adiponectin protects against the development of systolic dysfunction following myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 6, pp. 1065–1074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Shibata, K. Sato, D. R. Pimentel et al., “Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms,” Nature Medicine, vol. 11, no. 10, pp. 1096–1103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan, “Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart,” Cardiovascular Research, vol. 79, no. 2, pp. 279–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Plant, B. Shand, P. Elder, and R. Scott, “Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins,” Diabetes and Vascular Disease Research, vol. 5, no. 2, pp. 102–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. C. Caselli, A. D'Amico, M. Cabiati, T. Prescimone, S. Del Ry, and D. Giannessi, “Back to the heart: the protective role of adiponectin,” Pharmacological Research, vol. 82, pp. 9–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  140. E. C. M. Mariman and P. Wang, “Adipocyte extracellular matrix composition, dynamics and role in obesity,” Cellular and Molecular Life Sciences, vol. 67, no. 8, pp. 1277–1292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. Z. Chen, I.-C. Peng, W. Sun et al., “AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633,” Circulation Research, vol. 104, no. 4, pp. 496–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Wang, T.-Y. Xu, Y.-F. Guan, D.-F. Su, G.-R. Fan, and C.-Y. Miao, “Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide,” Cardiovascular Research, vol. 81, no. 2, pp. 370–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. M.-A. Ewart, C. F. Kohlhaas, and I. P. Salt, “Inhibition of tumor necrosis factor α-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2255–2257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells,” Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. Y. Arita, S. Kihara, N. Ouchi et al., “Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell,” Circulation, vol. 105, no. 24, pp. 2893–2898, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Matsuda, I. Shimomura, M. Sata et al., “Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis,” The Journal of Biological Chemistry, vol. 277, no. 40, pp. 37487–37491, 2002. View at Publisher · View at Google Scholar · View at Scopus
  147. C. Kobashi, M. Urakaze, M. Kishida et al., “Adiponectin inhibits endothelial synthesis of interleukin-8,” Circulation Research, vol. 97, no. 12, pp. 1245–1252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. P. Zhang, Y. Wang, Y. Fan, Z. Tang, and N. Wang, “Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 1, pp. 67–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. I. Afanas'ev, “ROS and RNS signaling in heart disorders: could antioxidant treatment be successful?” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 293769, 13 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. R. Meng, Z. Pei, A. Zhang et al., “AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway,” Archives of Biochemistry and Biophysics, vol. 511, no. 1-2, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. P. S. Jhund and J. J. V. McMurray, “Heart failure after acute myocardial infarction a lost battle in the war on heart failure?” Circulation, vol. 118, no. 20, pp. 2019–2021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. C. J. Weinheimer, L. Lai, D. P. Kelly, and A. Kovacs, “Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure,” Clinical and Experimental Pharmacology and Physiology, vol. 42, no. 1, pp. 33–40, 2015. View at Publisher · View at Google Scholar
  153. M. Y. Baden, Y. Yamada, Y. Takahi et al., “Association of adiponectin with blood pressure in healthy people,” Clinical Endocrinology, vol. 78, no. 2, pp. 226–231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. A. M. Thøgersen, S. Söderberg, J.-H. Jansson et al., “Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 1, pp. 33–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. S. M. Wallerstedt, A.-L. Eriksson, A. Niklason, C. Ohlsson, and T. Hedner, “Serum leptin and myocardial infarction in hypertension,” Blood Pressure, vol. 13, no. 4, pp. 243–246, 2004. View at Publisher · View at Google Scholar · View at Scopus